These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17614238)

  • 21. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.
    Munakata J; Hazard E; Serrano D; Klingman D; Rupnow MF; Tierce J; Reed M; Lipton RB
    Headache; 2009 Apr; 49(4):498-508. PubMed ID: 19245386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoting health at the workplace: challenges of prevention, productivity, and program implementation.
    Young JM
    N C Med J; 2006; 67(6):417-24. PubMed ID: 17393702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The burden of illness associated with renal cell carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
    Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Workers with alcohol and drug addiction problems. Consensus Document of the Study Group on Hazardous Workers].
    Magnavita N; Bergamaschi A; Chiarotti M; Colombi A; Deidda B; De Lorenzo G; Goggiamani A; Magnavita G; Ricciardi W; Sacco A; Spagnolo AG; Bevilacqua L; Brunati MM; Campanile T; Cappai M; Cicerone M; Ciprani F; Di Giannantonio M; Di Martino G; Fenudi L; Garbarino S; Lopez A; Mammi F; Orsini D; Ranalletta D; Simonazzi S; Stanzani C
    Med Lav; 2008; 99 Suppl 2():3-58. PubMed ID: 19248471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic syndrome in a workplace: prevalence, co-morbidities, and economic impact.
    Schultz AB; Edington DW
    Metab Syndr Relat Disord; 2009 Oct; 7(5):459-68. PubMed ID: 19450154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [How to measure efficiency of health investments in enterprises: selected issues].
    Rydlewska-Liszkowska I
    Med Pr; 2005; 56(6):467-74. PubMed ID: 16613372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm.
    Kessler RC; Lane M; Stang PE; Van Brunt DL
    Psychol Med; 2009 Jan; 39(1):137-47. PubMed ID: 18423074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Economic evaluation of prevention programmes for occupational health and safety: the pertinence of cost-benefit analysis].
    Antonopoulou L; Targoutzidis A
    Sante Publique; 2010; 22(1):23-35. PubMed ID: 20441621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?
    Ettner SL; Huang D; Evans E; Ash DR; Hardy M; Jourabchi M; Hser YI
    Health Serv Res; 2006 Feb; 41(1):192-213. PubMed ID: 16430607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substance abuse: myths and realities in the corporate sector.
    Merrill JC
    Bus Health; 2001 Jan; 19(1):31, 34-6. PubMed ID: 11200393
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.
    Puolakka K; Kautiainen H; Mottonen T; Hannonen P; Korpela M; Hakala M; Luukkainen R; Vuori K; Blåfield H; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(2):96-103. PubMed ID: 19274516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving efficiency and value in palliative care with net benefit regression: an introduction to a simple method for cost-effectiveness analysis with person-level data.
    Hoch JS
    J Pain Symptom Manage; 2009 Jul; 38(1):54-61. PubMed ID: 19615627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Labor market productivity costs for caregivers of children with spina bifida: a population-based analysis.
    Tilford JM; Grosse SD; Goodman AC; Li K
    Med Decis Making; 2009; 29(1):23-32. PubMed ID: 18725406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of corporate medical programs.
    Jacobs P; Chovil A
    J Occup Med; 1983 Apr; 25(4):273-8. PubMed ID: 6406653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study tracks costs of treating employees' drug problems.
    Kim H
    Mod Healthc; 1991 Jan; 21(3):18. PubMed ID: 10170655
    [No Abstract]   [Full Text] [Related]  

  • 37. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global cost-benefit analysis of water supply and sanitation interventions.
    Hutton G; Haller L; Bartram J
    J Water Health; 2007 Dec; 5(4):481-502. PubMed ID: 17878562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Models of workers' health and safety insurance in the selected European Union member states: certain economic problems].
    Rydlewska-Liszkowska I
    Med Pr; 2007; 58(6):511-9. PubMed ID: 18421933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Charting the sea of employee addiction.
    Russo V; Halpern Z
    Occup Health Saf; 1992 Dec; 61(12):35-6, 65. PubMed ID: 1475070
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.